Hydralazine, a direct arteriole vasodilator, is essential for managing hypertension and hypertensive emergencies. It inhibits inositol trisphosphate (IP3)-induced calcium release in smooth muscle cells, reducing peripheral vascular resistance and triggering a compensatory baroreceptor-mediated increase in venous return and cardiac output. Beyond its cardiovascular effects, recent studies have highlighted hydralazine's reno-protective benefits, making it a valuable option for patients with acute kidney injury and chronic kidney disease. Its high solubility, long half-life, and non-dialyzable nature make it particularly effective in hypertensive patients with renal comorbidities.
Join us for an insightful session, “Managing Hypertensive Emergencies: The Role of Hydralazine in Renal Compromise,” led by esteemed nephrologist Dr. Vaibhav Keskar on 12th November at 6:00 PM IST. Don't miss…
